CYBX Profile
Cyberonics,
Inc. (CYBX) is a medical technology company that specializes in
developing and manufacturing neuromodulation devices. The company's
products are used in the treatment of epilepsy and other neurological
disorders.
Cyberonics' primary product is the Vagus Nerve
Stimulation Therapy (VNS Therapy) System, which is used to treat
patients with epilepsy that are not well-controlled by medication. The
VNS Therapy System involves the implantation of a small device under
the skin, which delivers electrical signals to the vagus nerve in the
neck.
Cyberonics was founded in 1987 and is headquartered in
Houston, Texas. As of my knowledge cutoff of September 2021, the
company was performing well financially, with strong revenue and
earnings growth in recent years. The company's revenue for the fiscal
year 2020 was $344 million, representing an increase of 6.2% compared
to the previous year. Net income for the same period was $65.6
million, an improvement from $49.3 million in the previous year.
Cyberonics has a market capitalization of approximately $1.4
billion as of September 2021, and its stock is listed on the NASDAQ
stock exchange under the ticker symbol CYBX.
The medical
technology industry is subject to various risks, including regulatory
risks, competitive risks, and changes in healthcare policies. However,
Cyberonics' focus on developing innovative neuromodulation devices and
its strong financial performance should position it well for continued
success in
|
